Suitability and Accessibility Evaluation of Imrecoxib
10.3870/j.issn.1004-0781.2025.02.011
- VernacularTitle:艾瑞昔布的适宜性和可及性评价
- Author:
Mingxia CHENG
1
;
GULINIGEER·AINIWAER
;
Yuan ZHANG
;
Mengdi SHENG
;
Han XIE
;
Weihong GE
Author Information
1. 南京中医药大学鼓楼临床医学院药学部,南京 210008
- Publication Type:Journal Article
- Keywords:
Imrecoxib;
Nonsteroidal anti-inflammatory drugs;
Class 1.1 new drugs;
Accessibility;
Suitability
- From:
Herald of Medicine
2025;44(2):239-245
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the suitability and accessibility of the national Class 1.1 new drug imrecoxib,and provided reference for rational use of drugs in clinical practice.Methods Constructing a suitability and accessibility evaluation system for the national Class 1.1 new drug imrecoxib based on the Delphi method and evaluated through a survey questionnaire.Results After two rounds of expert inquiries,the authority coefficient of the experts was 0.795,the coefficient of variation of the third level indicator of expert opinions was 0.15,and the coordination coefficient was 0.244.Finally,the evaluation index system for the suitability and accessibility of nonsteroidal anti-inflammatory drugs was determined.The evaluation index system including 2 primary indicators,8 secondary indicators,and 39 tertiary indicators.173 survey questionnaires were distributed in total.The results indicate that in terms of suitability,imrecoxib has good suitability in both drug use and drug technology characteristics;In terms of accessibility,the price level of imrecoxib is relatively low,and its affordability,accessibility,and patient acceptability are good.Conclusions This study comprehensively evaluated the suitability and accessibility of the national Class 1.1 new drug imrecoxib,provided a reference basis for clinical rational use and regulatory decision-making.
